Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

September 28th, 2015

Japan’s Zilver® PTX® two-year results support global evidence for drug-eluting stents in the SFA

Bloomington, Ind. — Dr. Kimihiko Kichikawa, Department of Radiology at Nara Medical University in Japan, reported two-year results of the Zilver® PTX® post-market surveillance (PMS) study on September 27, 2015, in Lisbon, Portugal. Dr. Kichikawa presented initial target data on lesion revascularization (TLR) at Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015, a European meeting for interventional radiologists and vascular specialists.

The two-year results indicate a continued low rate of revascularization in patients with complex lesions and comorbidities. No exclusion criteria were in the Japan PMS. The 1,075 lesions were complex, with an average lesion length of 14.7 cm, 42% total occlusions, and 19% in-stent restenosis (ISR). In addition, 21% of Japanese patients in the PMS had critical limb ischemia (CLI), 59% had diabetes, and 44% had renal disease.

The two-year freedom from TLR is 85.0%.

According to Dr. Kichikawa, the positive two-year Japan PMS results are consistent with other Zilver PTX trials and confirm the long-term benefits of Zilver PTX technology.

Two other major Zilver PTX trials showed similar numbers at the two-year mark. Freedom from TLR was 85.7% in the randomized controlled trial (RCT) and was 83.3% in the single-arm study (SAS). The three trials enrolled more than 2,000 patients.

“The consistency of these three Zilver PTX studies are what we’ve now come to expect,” said Mark Breedlove, vice president of Cook Medical’s Peripheral Interventional division. “We have seen positive numbers even at five years post-implantation, which is extraordinary in vascular device studies. It’s a very good sign for vascular disease patients that this drug-eluting stent provides such meaningful improvement, even for real-world patients whose disease has already progressed to such a critical level.”

Zilver PTX has been approved for use in the European Union since August 2009 and in the United States and Japan since 2012. It is now approved in 48 countries.

Dr. Kimihiko Kichikawa is a paid consultant of Cook Medical.

About Cook Medical

Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today, we are combining medical devices, biologic materials, and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees, and our communities. Find out more at, and for the latest news, follow us on Twitter, Facebook and LinkedIn.